Showing results (281-290 of 353) with videos related to

Sort By:
Pageof 36
Journal of the National Comprehensive Cancer Network : JNCCN|October 5, 2016
High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male SexZheng Zhou, Alfred W Rademaker, Leo I Gordon, et al.
JAMA Network Open|January 19, 2024
Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in ChildrenAndrea C Lo, Amy Liu, Qi Liu, et al.
Blood|July 28, 2018
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PETDavid J Straus, Sin-Ho Jung, Brandelyn Pitcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2012
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practicesA K Nooka, C Nabhan, X Zhou, et al.
Blood Advances|April 10, 2024
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101Tracy T Batchelor, Sharmila Giri, Amy S Ruppert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin LymphomaRadhakrishnan Ramchandren, Ranjana H Advani, Stephen M Ansell, et al.
Hematological Oncology|January 19, 2021
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 studyMartin Hutchings, John Radford, Stephen M Ansell, et al.
British Journal of Haematology|June 13, 2009
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphomaJonathan W Friedberg, Jennifer L Kelly, Donna Neuberg, et al.
Leukemia & Lymphoma|July 9, 2025
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201Charalambos Andreadis, Olivia Bobek, Eric D Hsi, et al.
Journal of the National Cancer Institute. Monographs|November 16, 2017
State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion ReportDan Xi, Ting Bao, Qi Chen, et al.
Pageof 36